MedTrace Logo

Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer

NCT00466089 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2008-01-10

No results posted yet for this study

Summary

A phase II, multicenter, randomized trial of 3D Radiotherapy versus 3D Radiotherapy and erlotinib (Tarceva®) in patients with localized-unresectable (IA-IIIB) non-small cell lung cancer non susceptible for chemotherapy treatment, to compare safety and toxicity profile, and the progression-free survival in both arms of treatment (3D Radiotherapy versus 3D Radiotherapy + erlotinib) in patients who have not received previous chemotherapy.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Erlotinib (Tarceva®)

Erlotinib (Tarceva®), 150mg/day p.o during 6 months.

Sponsors & Collaborators

  • Dr. Enrique Martínez López

    collaborator UNKNOWN

  • Hospital of Navarra

    lead OTHER

Principal Investigators

  • Enrique Martínez, Dr. · Hospital de Navarra

  • Ana Mª Perez Casas, Dr. · Fundación Jimenez Diaz

  • Alejandro De la Torre, Dr. · Hospital Puerta de Hierro

  • Francesc Casas, Dr. · Hospital Clínic i Provincial de Barcelona

  • Nuria Viñolas, Dr. · Hospital Clínic i Provincial de Barcelona

  • Julian Minguez, Dr. · Hospital de Donostia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00466089 on ClinicalTrials.gov